Printer-friendly versionPrinter-friendly version

Prevention and control of perinatal transmission of hepatitis B and C.

June 01-02, 2017 - Vienna, Austria

Meeting objectives:

  • Overview of the current epidemiology of perinatal hepatitis B and C transmission;
  • Discuss the impact of perinatal transmission on the elimination goals of viral hepatitis;
  • Overview of the scientific evidence on prevention and control of perinatal HBV transmission through birth dose vaccination, HBIg and Treatment;
  • Overview of the scientific evidence on prevention and control of perinatal HCV transmission by treatment;
  • Coverage, impact verification and scientific relevance of birth dose vaccination;
  • Identify challenges and objectives to improve perinatal transmission and secure the success of the elimination goals by 2030;

Background document  - 2.9 Mb (.pdf)

Thursday 01 June

SESSION 1: OPENING AND OBJECTIVES
Chairs: John Ward and Paolo Bonanni

08:30-09:00

  • Welcome and opening
  • Introduction of the participants
  • Introduction of the VHPB
  • Objectives of the meeting:
  • Review of the meeting programme

SESSION 2: INTRODUCTION PERINATAL TRANSMISSION

09:00 - 09:20 Introduction of Perinatal transmission of hepatitis B - 552 kb (.pdf)
Noele Nelson

09:20 - 09:40 Perinatal HBV viremia in newborns of HBsAg(+) mothers is a transient phenomenon that does not necessarily imply HBV infection transmission - 1.8 Mb (.pdf)
Vana Papaevangelou

09:40 - 10:00 Perinatal transmission of hepatitis C virus -  3.4 Mb (.pdf)
Giuseppe Indolfi

10:00 - 10:20 Questions and discussion

SESSION 3: IS PERINATAL TRANSMISSION (STILL) AN ISSUE FOR THE ELIMINATION OF VIRAL HEPATITIS
Chairs: Vladimir Chulonov and Erika Duffell

10:40 - 11:00 Perinatal transmission of hepatitis B virus during pregnancy and delivery in Denmark - 788 kb (.pdf)
Nina Weis

11:00- 11:20 Outcomes of infants born to women infected with hepatitis B AND Characteristics of Pregnant Women With Hepatitis B Virus Infection in 5 US Public Health Jurisdictions, 2008-2012 - 424 kb (.pdf)
Sarah Schillie

11:20- 11:40 Mother-to-child transmission of hepatitis B in sub-Saharan Africa - 1.1Mb (.pdf)
Yusuke Shimakawa

11:40 - 12:00 Mother to child transmission, in Asia and Latin America (PAHO) - 2.7 Mb (.pdf)
Nick Walsh

12:00- 12:20 Viral hepatitis in pregnant women in England: results from two surveillance studies - 478 kb (.pdf)
Heather Bailey

12:20 - 12:40 Discussion

12:40 – 13:45 Lunch

 

SESSION 4: PERINATAL TRANSMISSION RISK FACTORS
Chairs: Alessandro Zanetti and Françoise Roudot-Thoraval

13:45 - 14:05 The Effect of Genotype/Subgenotype of Hepatitis B Virus on HBeAg Expression and Perinatal Transmission - 3.6 Mb (.pdf)
Anna Kramvis

14:05 - 14:25 Vertically acquired hepatitis C virus infection: Correlates of transmission and disease progression - 2.1 Mb (.pdf)
Silvia Garazzino

14:25 - 14:45 Increased Hepatitis C Virus (HCV) Detection in Women of Childbearing Age and Potential Risk for Vertical Transmission - United States and Kentucky, 2011-2014 - 554 kb (.pdf)
Noele Nelson

14:45 - 15:05 Questions & Comments

15:05- 15:30 Coffee break

 

SESSION 5: PREVENTION
Chairs: Mojca Maticic and Rui Tato Marinho

15:30 - 15:50 Antenatal screening for hepatitis C: Universal or risk factor based? - 0.4 Mb (.pdf)
Nazha Abughali

15:50 - 16:10 Questions & comments

16:10 - 16:30 Vertical transmission of hepatitis C: towards universal antenatal screening in the era of new direct acting antivirals (DAAs)? Short review and analysis of the situation in Switzerland - 1 Mb (.pdf)
Karoline Aebi-Popp

16:30 - 16:50 Should we treat hepatitis B positive pregnant women to prevent MTCT? - 1.9 Mb (.pdf)
Daniel Shouval

16:50 – 17:10 Questions & comments

17:10- 17:30 Cost-effectiveness of active-passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection Shortened Interval for Post vaccination Serologic Testing of Infants Born to Hepatitis B-Infected Mothers - 487 kb (.pdf)
Sarah Schillie

17:30- 17:50 Hepatitis B vaccine alone or with hepatitis B immunoglobulin in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis Adherence to perinatal hepatitis B prevention programmes - 1 Mb (.pdf)
Vana Papaevangelou

17:50 – 17:10 Questions

 

Friday 02 June

SESSION 5: PREVENTION (continued)
Chairs: Daniel Shouval and Fiona Godfrey

08:30 – 08:50 Control of perinatal HBV infection: WHO approach from success with timely birth dose to future perspectives in the context of triple elimination
Yvan Hutin

08:50 – 09:10 Questions & Comments

Session 6: POLICY RECOMMENDATIONS FOR PREVENTION OF PERINATAL TRANSMISSION

09:10– 10:10 Overview of existing guidelines and/or activities to prevent MTCT

  • ECDC - 878 kb (.pdf): Erika Duffell
  • CDC - 1.7 MB (.pdf): John Ward
  • WHO-Euro 1.3 Mb (.pdf): Liudmila Mosina/Antons Mozalevskis
  • EASL - 232 kb (.pdf): Petra Munda

10:10- 10:35 How Should Evidence-Based Medicine Be Used to Design Clinical Practice Guidelines for the Prevention of Perinatal Transmission of HBV From HBeAg-Positive Mothers?
Blaine Hollinger

10:35 – 10:40 Question and discussion

SESSION 7: WORKSHOP DISCUSSION
Chairs: Mark Kane – Pierre Van Damme

10:40 – 12:30 Workshop discussions: Identify challenges and objectives to improve perinatal transmission and secure the success of the elimination goals by 2030

12:30 – 13:30 Presentation Workshop conclusion

12:40 – 13:45 Lunch

SESSION 8: CONCLUSIONS
Chairs: Daniel Lavanchy and Liudmila Mosina

14:30 – 15:30 Presentation of the VHPB meeting conclusions by the rapporteur.
David FitzSimons

Tags: